VistaGen Therapeutics (NASDAQ:VTGN) Stock Crosses Below 50 Day Moving Average of $0.18

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGNGet Rating) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.18 and traded as low as $0.17. VistaGen Therapeutics shares last traded at $0.17, with a volume of 2,384,078 shares.

VistaGen Therapeutics Trading Down 3.6 %

The company has a market capitalization of $37.11 million, a price-to-earnings ratio of -0.55 and a beta of 1.09. The company has a fifty day moving average of $0.18 and a 200-day moving average of $0.16.

VistaGen Therapeutics (NASDAQ:VTGNGet Rating) last posted its quarterly earnings data on Tuesday, February 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. VistaGen Therapeutics had a negative return on equity of 158.24% and a negative net margin of 5,614.37%. The company had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.31 million. As a group, equities research analysts expect that VistaGen Therapeutics, Inc. will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Alliancebernstein L.P. boosted its holdings in shares of VistaGen Therapeutics by 76.8% during the 4th quarter. Alliancebernstein L.P. now owns 315,900 shares of the company’s stock worth $33,000 after purchasing an additional 137,200 shares during the last quarter. Morgan Stanley boosted its holdings in shares of VistaGen Therapeutics by 61.0% during the 4th quarter. Morgan Stanley now owns 249,386 shares of the company’s stock worth $26,000 after purchasing an additional 94,507 shares during the last quarter. GPS Wealth Strategies Group LLC boosted its holdings in shares of VistaGen Therapeutics by 3,444.8% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 253,205 shares of the company’s stock worth $25,000 after purchasing an additional 246,062 shares during the last quarter. State Street Corp boosted its holdings in shares of VistaGen Therapeutics by 44.6% during the 3rd quarter. State Street Corp now owns 5,632,066 shares of the company’s stock worth $857,000 after purchasing an additional 1,736,668 shares during the last quarter. Finally, Two Sigma Advisers LP acquired a new position in shares of VistaGen Therapeutics during the 3rd quarter worth approximately $36,000. 27.29% of the stock is currently owned by institutional investors and hedge funds.

About VistaGen Therapeutics

(Get Rating)

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy.

Further Reading

Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.